Tianjin Lisheng Pharmaceutical Co.,Ltd.

SZSE:002393.SZ

24.35 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 1,130.1631,146.5891,091.9411,140.8381,615.2761,503.6071,029.433846.853774.782773.7261,044.3981,117.068763.642737.972595.702592.538393.292349.443
Cost of Revenue 495.622486.28454.481439.505447.758427.121378.746365.428346.505347.123369.382428.415299.496295.386218.285241.409119.926105.902
Gross Profit 634.54660.309637.46701.3321,167.5181,076.487650.687481.425428.277426.603675.015688.653464.146442.586377.418351.129273.365243.541
Gross Profit Ratio 0.5610.5760.5840.6150.7230.7160.6320.5680.5530.5510.6460.6160.6080.60.6340.5930.6950.697
Reseach & Development Expenses 96.465105.977104.08776.7123.42994.298102.1964.21233.22641.49239.28940.62425.4923.30817.63117.30712.9820
General & Administrative Expenses 24.60926.46828.7372934.08528.38523.97420.0510.63420.55626.47625.37923.43917.7216.57214.81713.88464.455
Selling & Marketing Expenses 318.94336.017362.914424.416692.31660.393307.954193.373173.28195.802228.42216.156114.05496.98784.83786.80164.44267.199
SG&A 411.617362.485391.652453.415726.394688.779331.928213.423183.914216.357254.897241.535137.493114.707101.41101.61978.326131.653
Other Expenses -13.833108.38896.111113.141121.702-1.0220.21.9982.0394.4135.4565.2510.893.5736.3880.2561.0040.691
Operating Expenses 521.915576.85591.85643.256971.525903.134552.364366.206299.839338.344370.169366.775222.257199.643165.431162.745118.475136.522
Operating Income 112.625175.672136.908102.355220.148215.011130.626131.285133.624107.781347.969357.988386.006261.517195.275172.369154.738117.251
Operating Income Ratio 0.10.1530.1250.090.1360.1430.1270.1550.1720.1390.3330.320.5050.3540.3280.2910.3930.336
Total Other Income Expenses Net 296.569-57.3070.212-71.423-3.35540.63632.50318.0646.94523.81448.33141.197144.88422.125-10.433-15.8670.80710.88
Income Before Tax 409.194118.364137.1230.932216.793213.989130.826133.283135.384112.073353.177363.076386.773265.068201.554172.517155.697117.9
Income Before Tax Ratio 0.3620.1030.1260.0270.1340.1420.1270.1570.1750.1450.3380.3250.5060.3590.3380.2910.3960.337
Income Tax Expense 58.38624.75815.01522.31728.65629.01214.00917.67721.16719.18755.11561.33353.38245.80635.30329.05923.74418.968
Net Income 361.82893.607122.1058.615188.137184.978116.817115.606114.21492.884298.059297.105324.769203.395154.508132.008132.448100.226
Net Income Ratio 0.320.0820.1120.0080.1160.1230.1130.1370.1470.120.2850.2660.4250.2760.2590.2230.3370.287
EPS 1.970.510.670.0471.031.010.640.630.630.511.611.631.91.221.130.970.970.73
EPS Diluted 1.970.510.670.0471.031.010.640.630.630.511.611.631.91.221.130.970.970.73
EBITDA 179.93241.793212.709165.834304.416282.549195.072207.989172.574143.962379.023391.319406.118284.351225.02200.878168.756104.885
EBITDA Ratio 0.1590.2110.1950.1450.1880.1880.1890.2460.2230.1860.3630.350.5320.3850.3780.3390.4290.3